C difficile risk
Oral Bioavailability


75 mg PO BID x 5 days

Currently available data are insufficient to recommend a specific dose of oseltamivir for premature infants; it is strongly recommended that an Infectious Diseases physician or clinical pharmacist be consulted.

3 mg/kg/dose PO BID x 5 days

10 - 30 eGFR31 - 60 eGFR60+ eGFR30 mg PO daily x 5 days30 mg BID x 5 days75 mg PO BID x 5 days

General Information

Treatment and prophylaxis of influenza A and B.


  • Compatible.

  • Reports describing the use of oseltamivir during human pregnancy do not suggest a significant risk of developmental toxicity.

  • Influenza infection in pregnancy is a high-risk condition, the maternal benefit far outweighs the unknown risk, if any, to the embryo or fetus.


  • Compatible.

  • Oseltamivir and its active metabolite are poorly excreted into breastmilk.

  • Maternal dosages of 150 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants.

  • Therapeutic doses of oseltamivir are given to newborns with influenza.

  • GI upset common

  • Rare - Stevens Johnson Syndrome

  • Neuropsychiatric side effects reported

No significant drug interactions.

Will only treat Influenza A and B. Does NOT treat RSV, parainfluenza, human metapneumovirus, adenovirus, or other common viral pathogens. Discontinue if influenza test results return negative.

Note that pregnant and postpartum (up to 4 weeks) are considered high risk of complications from influenza and treatment is recommended in this population.

Greatest benefit is seen if treatment is started within 48 h of symptom onset, however, treatment may still be beneficial and should be started in high risk patients, and hospitalized patients with severe, complicated or progressive illness if > 48 hours.

Antimicrobial class: Antiviral - neuraminidase inhibitor.